Status:
COMPLETED
Recombinant Activated Factor VII in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia
Lead Sponsor:
Universiti Sains Malaysia
Conditions:
Massive Hemorrhage
Massive Blood Loss
Eligibility:
All Genders
Brief Summary
This is a retrospective descriptive study, to study the treatment indications, changes in transfusion need, coagulation profiles changes and clinical outcome (survival, complication) of non-haemophili...
Detailed Description
Effective hemostasis can be life-saving. However, there is still lack of an ideal hemostatic drug which is safe and effective. Recombinant activated factor VII (rFVIIa; Novo Nordisk, Bagsvaerd, Denma...
Eligibility Criteria
Inclusion
- All patient with massive bleeding who had received rFVIIa from year 2006 to year 2016.
- Massive bleeding criteria
- Loss of one blood volume within a 24 hour
- 50% blood volume loss within 3 h
- Rate of loss of 150 ml/min
Exclusion
- Haemophilia patient who received rFVIIa
- Poor documentation / record unavailable in HUSM
Key Trial Info
Start Date :
August 21 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 15 2017
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT03251547
Start Date
August 21 2017
End Date
November 15 2017
Last Update
October 10 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universiti Sains Malaysia
Kota Bharu, Kelantan, Malaysia, 16150